The central effects of the beta-adrenergic blocking agent INPEA.
D000200:Action Potentials / Q000187:drug effects; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001143:Arousal / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D002415:Cats; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects*; D002552:Cerebral Ventricles; D004569:Electroencephalography; D004983:Ethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D005071:Evoked Potentials / Q000187:drug effects; D005239:Fear; D007267:Injections; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007536:Isomerism; D008564:Membrane Potentials / Q000187:drug effects*; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D009578:Nitrobenzenes / Q000008:administration & dosage / Q000494:pharmacology; D010627:Phenethylamines / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D009578:Nitrobenzenes; D010627:Phenethylamines